Mitapivat (AG-348) Demonstrates Safety, Tolerability, and Improvements in Anemia, Hemolysis, Oxygen Affinity, and Hemoglobin S Polymerization Kinetics in Adults with Sickle Cell Disease: A Phase 1 Dose Escalation Study
Julia Xu(National Institutes of Health), Swee Lay Thein, Anna Conrey(National Institutes of Health), Laurel A. Menapace(National Institutes of Health), Maureen Lundt(National Institutes of Health), Heidi Mangus(Agios Pharmaceuticals (United States)), Eveline Gwaabe(National Institutes of Health), Penelope A. Kosinski(Agios Pharmaceuticals (United States)), Kristen E. Glass(National Institutes of Health), Peter Hawkins(Agios Pharmaceuticals (United States)), Laxminath Tumburu(National Institutes of Health), Quan Li(National Institutes of Health), Neal Jeffries(National Institutes of Health), William A. Eaton(National Institutes of Health), Charles Kung(Agios Pharmaceuticals (United States)), Lenny Dang(Millennium Engineering and Integration (United States)), Varsha Iyer(Agios Pharmaceuticals (United States)), Ingrid Frey(National Institutes of Health)
Cited by 9
Related Papers
Frequent Engagement of the Classical and Alternative NF-κB Pathways by Diverse Genetic Abnormalities in Multiple Myeloma
|Cancer Cell|2007|949
AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic <i>IDH2</i> Mutations
|Cancer Discovery|2017|457
The new International Classification of Diseases 11th edition: a comparative analysis with ICD-10 and ICD-10-CM
|Journal of the American Medical Informatics Association|2020|90